The investigators will perform an unbiased screen for the human genome content of circulating microRNAs. Standard HF biomarkers will be included so that the added value of these novel HFpEF miRNAs can be directly compared to established HF biomarkers. In this cohort of women who experienced pre-eclampsia and matched controls the investigators will profile miRNAs on a genome wide scale using total RNA from plasma. Differentially expressed miRNAs will be further investigated in relation to the pathogenesis of micro- and macrovascular disease. Selected miRNAs will be placed on a custom megaplex array and used to screen a cohort of patients with HFpEF. In patients with HFpEF the investigators will relate miRNA expression level to the circulating levels of angiopoietin-2/ang-1ratio's and micro-albuminuria. Part of the obtained blood and urine will be stored at the Biobank in Maastricht for future studies.